Are you helping a loved one get the best help and treatment for a lung cancer diagnosis? Or, maybe you are facing that diagnosis yourself.

Are you looking to find a clinical trial? Do you need help paying for your treatment medications? Do you need to know what the latest research says about treatments for a specific biomarker, like ALK or EGFR? The resources presented here can help you.

Resources & Organizations

This section is where you’ll find links to everything from clinical trials to prescription assistance and much more.

Latest Research

This section presents all of the latest lung cancer research articles presented on the LCFA website. Just click on the tags that interest you.

Current USPSTF Guidelines May Prevent Early Diagnosis of Lung Cancer

New Research Supports Standardization of Reporting for Incidental Findings in Lung Cancer Screening

New artificial intelligence tool can accurately identify cancer

Improving Lung Cancer Screening with Sybil

Study Uncovers Why Some Lung Cancers Avoid Immunotherapy

Pre- and Post-surgical Immunotherapy-based Treatment Significantly Improved Lung Cancer Outcomes

Inflammatory Biomarkers From Lung Cancer, Depression May Predict Survival Outcomes

Long-term study reveals ‘ever-changing’ nature of lung cancer

Estimated Lung Cancer Screening Rates “Extremely Low” Across Insurance Types

Lung Cancer Trial Has Broader Eligibility Criteria, Overcomes Barriers

Keytruda Meets Trial Goals for Non-Small Cell Lung Cancer Treatment

Osimertinib extends survival in early EGFR-mutated non-small cell lung cancer

quote “By understanding essentially what is driving the consumption of this critical fuel for this cancer, you can then potentially think about that this could be a good drug to target this cancer, specifically in terms of its metabolic needs,”

UCLA study finds drug could have ability to reduce lung cancer cell growth

Less Lung Tissue Removal Needed for Early-Stage Cancer, Study Finds

Trial Shows Significant Disease-free Survival for Patients Diagnosed With Non-small Cell Lung Cancer

New Treatment Options for Stage IV NSCLC With Driver Alterations

MIT researchers develop an AI model that can detect future lung cancer risk

Stage Shift Improves Lung Cancer Survival

Photo of a fire burning along the ridge with the article title in orange.

Human-Ignited Fires Caused 20,000 Premature U.S. Deaths

U.S. FDA Approves Mirati’s Lung Cancer Drug

Lung Cancer Survival High for Patients With Early, Screen-Detected Tumors

KRAS battle heats up as Mirati pressures Amgen with Keytruda combo show in lung cancer

Lung cancer screening saves lives. So why so do many at high risk not get one?

A new phase I/II clinical trial shows that repotrectinib had antitumor activity in participants with ROS-1-positive advanced non-small cell lung cancer

Novel drug shows promise in early-stage ROS1 clinical trials

GSK’s anti-TIM-3 antibody is moving into a pivotal trial after hitting the mark in the midphase portion of the study.

GSK hits go on pivotal TIM-3 lung cancer trial after phase 2 clears bar for advancement

FDA Fast Tracks Sapanisertib for NRF2-Mutated Squamous Lung Cancer

FDA approves Retevmo for lung cancer subset

Lumakras cut the risk of disease progression or death by 34%

Amgen’s Lumakras lung cancer data leave door open for KRAS competitors

Cancer breakthrough is a ‘wake-up’ call on danger of air pollution

Merck offers 5-year look at Keytruda’s landmark lung cancer trials. What’s next?

Enhertu breaks more ground, nabbing fast FDA nod in HER2-mutant lung cancer

How Smoking Cessation After a Lung Cancer Diagnosis Improves Overall Survival

Tagrisso plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

FDA Grants Orphan Drug Designation to THIO in Small Cell Lung Cancer

Early diagnosis of lung cancer among younger vs. older adults: Widening disparities in the era of lung cancer screening

Biomarker in Liquid Biopsy for Lung Cancer

Technology Lights Up Lung Cancer Tumors

Poor People Have Worst Lung Cancer Survival Rates

Growing Treatment Landscapes in Lung Cancer

photo of KRAS inhibitors researcher Miriam Molina Arcas, PhD

KRAS Inhibition May Improve Efficacy of Immune Checkpoint Blockade in Lung Cancer

Does Smoking Marijuana Increase the Risk of Lung Cancer? The Jury’s Still Out

Scientists Identify Rare (Rb-Proficient) Subtype of Small Cell Lung Cancer

MSK Scientists Identify Rare Subtype of Small Cell Lung Cancer

Standard of Care Change for Advanced NSCLC?

Slow the Spread of SCLC

Follow-Up Delayed After Lung Cancer Screening

Global lung cancer deaths in 2020: 1,796,144

Rise in Global Lung Cancer Rates Over 30 Years

Presurgery Opdivo + Chemo Cut Risk of Death by 43%

Racial Disparity in Lung Cancer Screening

Keytruda Reduces Risk of Recurrance

Deep Learning in NSCLC Care

Landmark Approval in Early-Stage Lung Cancer

Cold Water For Anti-PD-1 Candidate

Opdivo Granted Priority Review for NSCLC

Lung Cancer Risk Associated with Race

Wheels to Fight Lung Cancer

New Cancer Tool Gets Breakthrough Status

Medicare expands criteria for lung cancer screening making more people eligible. February, 2022.

Lung Cancer Screening Expanded by Medicare

Profile Lung Cancer in Never Smokers

Virtual Intervention for Patients With Lung Cancer

Lung Cancer Drives Overall Decline in Cancer Deaths

Breakthrough Therapy for EGFR NSCLC

Decreased Lung Cancer Deaths with Early Detection

Lung Cancer in Never Smokers

What Is Exon Insertion in NSCLC?

Imfinzi plus chemotherapy tripled survival

Biomarker testing decisions for lung cancer vary

Racial disparity in lung cancer treatment

Racial Disparities in Treatment and Survival for Lung Cancer

Lack of Adherence to Treatment Guidelines in NSCLC

Artificial Intelligence Blood Testing to Detect Lung Cancer

Five Year Lung Cancer Survival Update

Liquid Biopsy Simpler Sampling

Address Disparities in Lung Cancer Screening

Future of Liquid Biopsy

Bone Marrow Damage Reduced for ES-SCLC Patients

Lower Risk of Brain Mets

With up to 1 year of treatment with imfinzi, an estimated 43% of patients are still alive at 5 years.

Imfinzi increases five year survival to 43%

Role of Postoperative Radiotherapy in NSCLC

Diverse Workforce in Oncology

Cemiplimab-rwlc for NSCLC With High PD-L1

Immunotherapy + Chemo Boosts Response in Resectable NSCLC

New NSCLC Targeted Therapy Guidelines

Effectiveness of immuno-oncology in Medicare population.

Immuno-oncology Effectiveness in Medicare Population

Immunotherapy For Early-Stage Lung Cancer

Amivantamab Approved for EGFR Exon 20–Positive NSCLC

Sotorasib Approved for KRAS G12C NSCLC

New Treatment Approaches for Small-Cell Lung Cancer

Immune-boosting drug may help before lung cancer surgery

Treating NSCLC With Gene Mutations – Discussion with Dr. Gregory Masters

METex14 Patients See Improved Outcomes Following Savolitinib Treatment

Chromosomal Abnormality and Immunotherapy Response

Why Are ‘Never-Smokers’ Getting Lung Cancer?

Small-Cell Lung Cancer Guidelines

Lung Cancer Rates in the United States

Cancer Patients and the COVID Vaccine

Dr. Alice Berger receives NIH Merit Award

Expand Targeted Therapy for Lung Cancer

Lung Cancer Screening

Telehealth: Bridging the Digital Divide Is Still a Work In Progress

Lung Cancer Care Disparities: Are They Truly Inclusive?

Sotorasib Shows Benefits for KRAS G12C Mutation

Lorlatinib Approved for ALK-Positive NSCLC

Using Both, Immunotherapy and Chemotherapy Doubles Lung Cancer Survival

KRAS Mutation sees Promise for New Therapies

sclc patients show improved outcomes with combination therapy

Patients With Pretreated SCLC Have Improved Outcomes

IASLC Discusses Lung Cancer Care and Research Disparities

Tepotinib Approved for MET+ NSCLC

Breast cancer tops lung cancer as most diagnosed cancer

Why are lung cancer deaths in non-smokers on the rise?

Merck Pulls Keytruda for SCLC

J&J Antibody Hinders 94% of EGFR Lung Cancers

Antibody Hinders EGFR Lung Cancers

Study defines SCLC subtypes

How Biomarkers Impact Treatment Decisions

Genetics influence SCLC risk

Exploring Saliva in Early Lung Cancer Detection

Racial Disparities in Lung Cancer

60.3% of people in study think lung cancer patients are at least partially to blame for their illness

Lung Cancer Stigma: 10 Year Study

Fully half of female lung cancer patients never smoked

‘But I never smoked’: Never smokers and lung cancer

Lung Cancer patients - make your voices heard!

COVID-19 and Lung Cancer:

Liquid biopsy approved to test multiple genes

First Liquid Biopsy Approved for Multiple Genes

Lung Cancer Screenings Are Down

Tagrisso approved for adjuvant therapy for NSCLC

Tagrisso as Adjuvant Therapy for NSCLC Approved

Trailblazer KRAS treatment filed with FDA

KRAS G12C Treatment gets breakthrough therapy designation from FDA

KRAS G12C Treatment Breakthrough

2020 FDA Approvals of new lung cancer treatments

Treatments for Lung Cancer Newly Available in 2020

Unexpected Finding Reveals New Target for Aggressive Form of Lung Cancer

Aggressive Lung Cancer and new target

Lung Cancer Surgery: Women fare better than men

New KRAS drug could become standard of care for patients with G12C mutation

KRAS G12C mutation drug shows ‘positive’ Phase II results

Targeted therapy effective for RET

Have lung cancer patients experienced changes in treatment due to COVID-19?

Treatment Changes Due to COVID-19

Combination EGFR Therapy Boosts Survival in Early Lung Cancer

KRAS drug tackles 32% of Lung Cancers

RET Fusion-Positive NSCLC treatment gets FDA approval

RET Fusion-Positive NSCLC Treatment Gets Approval

Pan-tumor liquid biopsy gets FDA approval

Pan-Tumor Liquid Biopsy Gets Approval

MET-targeting lung cancer drug gets quick refiew

MET-targeting lung cancer drug gets quick review

RET inhibitor for lung cancer

racial disparity in lung cancer incidence

Racial disparities in lung cancer

Patient having chemotherapy treatment for SCLC

FDA Accepts NDA for Trilaciclib for SCLC

Lung Cancer Mortality Rates Drop Sharply

Improved Progression-Free Survival

Treatments Expand for EGFR-positive NSCLC

FDA AApproves small cell lung cancer treatment

FDA Approves Small Cell Lung Cancer (SCLC) Treatment

COVID19 severity and lung cancer

Tagrisso cuts lung cancer recurrence by 83%

Nivolumab plus Ipilimumab and Chemotherapy Approved for First-Line Treatment

Combination Therapy Aproved for First-Line Treatment

FDA approves treatment for NSCLC with MET Exon 14 skipping

NSCLC with MET exon 14 skipping Treatment Approved

End the Debate on Biomarker Testing for NSCLC

New guidelines for lung cancer screenings

African Americans and Lung Cancer Screening

lung cancer treatment progress over the past decade

Lung Cancer Treatment Progress Over the Last Decade

High BMI Linked to Better Immunotherapy Outcomes for NSCLC

Immunotherapy and BMI

Testing lung cancer patients for COVID-19

Testing Patients with Lung Cancer for COVID-19

Conducting Clinical Trials During Coronavirus Pandemic

Does Delaying ALK+ Treatment Impact Survival?

Durvalumab Approved for SCLC

African American Lung Cancer Patients less likely to receive lung cancer imaging

Coronavirus and Cancer: 1-2 Punch

When Cancer And Coronavirus Collide

Biomarker Testing and CT Screening Vital for Lung Cancer

Faulty Immune System May Lead to Lung Cancer

World Health Organization classifies air pollution as a carcinogen

Is Lung Cancer Related to Air Pollution?

Acquired Drug Resistance Strategy

Death Rate Drop: Lung Cancer Research Key

Small Cell Lung Cancer (SCLC)

Treatment Refusal for Small Cell Lung Cancer

How Are We Failing Lung Cancer Patients so Miserably?

Liquid Biopsies and NSCLC

Lung cancer screening guidelines do not detect disease among first responders.

Inadequate Lung Cancer Screening Guidelines for First Responders

Liquid Biopsies and Molecular Testing in Lung Cancer

Nasal-Swab Lung Cancer Test

Tecentriq: IMpower-ing results

MET Treatment Gets Breakthrough Designation

RET Drug Shrinks Tumors in Trial

Small Cell Lung Cancer: Immunotherapy Infinzi prolings survival

I/O Imfinzi prolongs survival

TMB and Lung Cancer Treatment

KRAS Treatment Shows Promise

FDA Approves entrectinib for ROS1 and NTRK

Entrectinib approved for ROS1 and NTRK

Liquid Biopsy: Are We Ready for a ‘Blood-First’ Approach?

Long-Term Survival for EGFR+

Blood Test Could Identify Potential Lung Cancer Markers

What could a clinical trial navigator do for you?

Clinical Trial Navigators

FDA approves Keytruda for SCLC

The Relationship Between Air Pollution and Lung Cancer in Nonsmokers

What good is it to cure cancer if we routinely fail to deliver that cure?

What good is it to be able to cure cancer if we routinely fail to deliver that cure?

Artificial intelligence and cancer

Know Your Genes: Testing for Genomic Mutations in Lung Cancer

Lung Cancer Stigma: Not Just the Patient’s Problem

Brushing airway tissue to predict the development of lung cancer

Could invigorating the immune system prevent lung cancer?

Precision of Liquid Biopsy and Osimertinib Resistance

Current Open Clinical Trials

FDA approves new treatment for extensive-stage small cell lung cancer

El Paso County Public Health advises people to test homes for radon

Antibiotics or anti-inflammatory drugs may help combat lung cancer

New treatment options for ROS1, BRAF, and NTRK biomarkers in lung cancer

New Treatment Options for ROS1, BRAF, and NTRK Alterations in NSCLC

New study predicts which lesions will become cancerous

Molecular profiling could catch lung cancer early and lead to new treatments

New Protein found linked to lug cancer treatment resistance

New Protein Found Linked to Lung Cancer Treatment Resistance

How bias in the medical community hurts lung cancer patients

What happens when the doctor blames you for your own cancer?

Patients now living a median 6.8 years after stage IV ALK+ lung cancer diagnosis

Lung Cancer Deaths are 28 Percent Lower in California

Appropriate biomarkers needed in patient selection for immunotherapy

First-Line Immunotherapy Combo Fails to Improve Survival in Lung Cancer Trial

New FDA Approval: Combination therapy for lung cancer

FDA Approves Atezolizumab Combination

Policy changes needed for access to lung cancer research.

Policy changes needed for access to lung cancer treatments

New DNA sequencing test credited with saving his life

Personalized Medicine for NTRK Fusion-Positive Solid Tumors

Women with lung cancer live longer than men

After Decades, New Standard of Care in Small Cell Lung Cancer

Can body fluids help spot lung cancer?

Air Pollution Increases Lung Cancer Risk in Nonsmokers

Lung cancer patient and activist, Janet Freeman-Daily with Dr. Russ Camidge, University of Colorado

The Power of Patients

Safe, Effective Treatment for Early-Stage Lung Cancer

Anti-cancer treatment designed to lower risk of cancer’s return

Combination Therapy Study Reduces Risk of Death by Half

Broad-Based Testing: Will it Improve Survival?

FDA Approves Opdivo for Small Cell Lung Cancer

Researchers Use Big Data to Predict Immunotherapy Responses

Blood test found that can accurately identify lung cancer patients who could benefit from immunotherapy.

Liquid Biopsy Could Ease the Way to Immunotherapy for Lung Cancer

Lung cancer mortality rates among women expected to increase.

Lung cancer mortality rates among women projected to increase

Could a Simple Blood Test Detect Early-Stage Lung Cancer?

Biomarker blood test better able to identify smokers who later develop lung cancer

Blood test improves lung cancer risk assessment for smokers

Can combination therapy increase lung cancer survival

Combination Therapy New Standard of Care for Squamous NSCLC

UCLA Clinical Trials - May and June, 2018

New Combination Therapy Clinical Trial for UCLA

New non-invasive method to detect lung cancer now in clinical trial

New Noninvasive Method for Lung Cancer Screening

Why non-smokers are getting lung cancer

US Vets 75% more likely to develop lung cancer

Lung Cancer Research gains $6,000,000 for 2019

Combination Therapy for Small Cell Lung Cancer

Study: Keytruda better than chemo against advanced lung cancer

Risk of LC drops within 5 years of quitting smoking

New research finds lung cancer risk drops substantially within five years of quitting smoking

Lung cancer rates in young women raise concerns

Low Lung Cancer Screening Rate

Immunotherapy Combination Increases Lung Cancer Survival

Testing for all lung cancer mutations at once found cost effective

Attention: Extensive-stage small cell lung cancer patients

New liquid biopsy-based cancer model reveals data on Small Cell Lung Cancer

New liquid biopsy-based cancer model reveals data on deadly lung cancer

What Is EGFR and How Does It Relate to Lung Cancer?

Immuno therapy scores big win against lung cancer in study

NSCLC with EGFR gets new first-line treatment

NSCLC with EGFR mutations gets new first-line treatment approved by FDA

ALK-positive non-small cell lung cancer gets boost from Lorlatinib

Scientists identify 170 potential lung cancer drug targets

LCFA Grant recipient gets write-up in New England Journal of Medicine

Dr. Kellie Smith: Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Lung cancer patients live longer with immuno-therapy

Lung Cancer Patients Live Longer With Immune Therapy

Outpatient Immunotherapy for Lung Cancer

Tecentriq plus chemo cut risk of death in type of lung cancer

UCLA Opens New Trial for Stage IV NSCLC Patients

FDA Approves 4-Week Nivolumab Dosing Schedule

Inhalation to be Used in New Trial for Second-Line NSCLC Patients

Merck’s Ace Keytruda Impresses Again, Stuns in Phase III Lung Cancer Trial

FDA Expands Afatinib’s Approval for Lung Cancer

Many Elderly Lung Cancer Patients Receive No Treatment

Seeking Consensus Amid Abundant New Lung Cancer Data

Targeted Therapies Convey Survival Benefit in Patients With Lung Cancer

The Biggest Cancer News Of 2017? ‘CAR-T Cells, Hands Down’

Will Immunotherapy And Radiation Be Combined In Lung Cancer Treatment?

It’s Crucial That Patients Identify The Mutations Driving Their Lung Cancers

UCLA Lung Cancer Screening and Early Detection

Dr. David Carbone, The Ohio State University

Lung Cancer: Is Your Doctor Screening You for the Best Treatment?

Blue Ribbon Panel Presentation to National Cancer Advisory Board for Cancer Moonshot

Videos

In this section, you’ll find interviews with the key opinion leaders in lung cancer research on the topics pertinent to lung cancer patients, survivors and caregivers.

Advances in Lung Cancer Research

Advocacy – Lung Cancer Foundation of America (LCFA)

Biopsies and Tissue Sample Size

Caregivers

Clinical Trials

Deadly Dancer

Early Detection

Everyday Stories and Realities of Lung Cancer

Findings from the National Lung Screening Trial

Genetic Mutations in Lung Cancer

Hope

Dr. Julie Brahmer, Sidney Kimmel Comprehensive Cancer Center

How To Get Your Tumor Tested

I’ve Got Lung Cancer

LCFA Grants: How They Help

Thumbnail of Dr. Heather Wakalee and the stigma of lung cancer

Lung Cancer Stigma

Need For Funding

Our Mission

Pace of Research

Research

Second Opinions

Thumbnail of Dr. David Carbone discussing lung cancer treatments

Selecting A Doctor

Targeted Therapies

Using Early Detection to Improve Patient Outcomes

What Does Dr. Donington Research?

Why Is Targeted Therapy Important